Study progress on pharmacogenomics of sodium-glucose linked transporter 2 inhibitors
- VernacularTitle:钠-葡萄糖耦联转运体2抑制剂的药物基因组学研究进展
- Author:
Yongru ZHUANG
1
,
2
;
Jinfang SONG
1
Author Information
1. Dept. of Pharmacy，the Affiliated Hospital of Jiangnan University，Jiangsu Wuxi 214000，China
2. School of Pharmacy，Xuzhou Medical University，Jiangsu Xuzhou 221000，China
- Publication Type:Journal Article
- Keywords:
gene polymorphism;
SGLT2i;
individual differences;
pharmacogenomics;
pharmacokinetics;
pharmacodynamics
- From:
China Pharmacy
2024;35(14):1790-1794
- CountryChina
- Language:Chinese
-
Abstract:
Sodium-glucose linked transporter 2 inhibitors（SGLT2i） are novel oral hypoglycaemic agents and are widely used for hypoglycemic therapy in patients with type 2 diabetes mellitus， but differences in the genetic backgrounds of patients often lead to variable responsiveness to drug therapy. By summarizing the pharmacogenomic studies of SGLT2i， the article found that the genetic variants of UGT1A9， UGT2B4， SLC5A2， ABCB1， PNPLA3 and WFS1 may influence the pharmacokinetics of SGLT2i and the external hypoglycemic effects of SGLT2i in improving non-alcoholic fatty liver disease， weight loss and so on， but there is no clinical evidence that genetic polymorphisms affect the hypoglycemic efficacy of SGLT2i.
